1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A series of potent and selective dopamine D3 receptor antagonists

Journal of Medicinal Chemistry

Volumn 50, Issue 21, 2007, Pages 5076-5089

  Micheli, Fabrizio ^a   Bonanomi, Giorgio ^a   Blaney, Frank E ^b   Braggio, Simone ^a   Capelli, Anna Maria ^a   Checchia, Anna ^a   Curcuruto, Ornella ^a   Damiani, Federica ^d   Di Fabio, Romano ^a   Donati, Daniele ^a   Gentile, Gabriella ^a   Gribble, Andy ^b   Hamprecht, Dieter ^a   Tedesco, Giovanna ^a   Terreni, Silvia ^a   Tarsi, Luca ^a   Lightfoot, Andrew ^b   Stemp, Geoff ^b   MacDonald, Gregor ^b   Smith, Alex ^b   Pecoraro, Michela ^a   Petrone, Marcella ^a   Perini, Ornella ^a   Piner, Jacqui ^b   Rossi, Tino ^a   Worby, Angela ^b   Pilla, Maria ^a   Valerio, Enzo ^a   Griffante, Cristiana ^a   Mugnaini, Manolo ^a   Wood, Martyn ^b   Scott, Claire ^b   Andreoli, Michela ^a   Lacroix, Laurent ^b   Schwarz, Adam ^a   Gozzi, Alessandro ^a   Bifone, Angelo ^a   Ashby Jr , Charles R ^c   Hagan, Jim J ^b   Heidbreder, Christian ^a   more..

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ST JOHN'S UNIVERSITY   (United States)

^d EUROPEAN PATENT OFFICE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOL 3 YL THIOPROPYLTETRAHYDROBENZAZEPINE DERIVATIVE; 3 [2 [4 [[3 [3 (5 METHYL 1,2,4 OXADIAZOLYL)]PHENYL]CARBOXAMIDO]CYCLOHEXYL]ETHYL] 7 METHYLSULFONYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; ACETYLCHOLINE; ALCOHOL; COCAINE; DEXAMPHETAMINE; DOFETILIDE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NICOTINE; PYRAZOLE DERIVATIVE; SB 414796; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BRAIN BLOOD VOLUME; BRAIN REGION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; IN VIVO STUDY; INSTRUMENTAL CONDITIONING; NONHUMAN; PLACE PREFERENCE; PLASMA CLEARANCE; PREFRONTAL CORTEX; RAT; RECEPTOR AFFINITY;

ACETYLCHOLINE; ADMINISTRATION, ORAL; ALCOHOL DRINKING; ANIMALS; BENZAZEPINES; BRAIN; COCAINE; CONDITIONING, OPERANT; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; MODELS, MOLECULAR; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D3; RECEPTORS, HISTAMINE H1; STRUCTURE-ACTIVITY RELATIONSHIP; TOBACCO USE DISORDER; TRIAZOLES;

EID: 35348917640     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0705612     Document Type: Article

References (51)

1. 3) as a target for neuroleptics. Nature 1990, 347, 146-151.
2. 3 receptor in the rat brain. Neuroscience 1995, 65, 731-745.
3. 3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 2000, 20, 8677-8684.
4. 2 receptor expressing neurons. Neuropsychopharmacology 1999, 20, 60-80.
5. 3 receptor mRNA and binding sites in human brain. Brain Res. Mol. Brain Res. 1993, 18, 187-192.
6. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 1998, 779, 58-74.
7. 3 receptors in drug addiction: a review of pharmacological evidence. Brain Res. Rev. 2005, 49, 77-105.
8. Joyce, J. N.; Millan, M. J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today 2005, 10, 917-25.
9. Micheli, F.; Heidbreder, C. Selective dopamine D3 receptor antagonists: A review 2001-2005. Recent Pat. CNS Drug Discovery 2006, 1, 271-288.
10. Newman, A. H.; Grundt, P.; Nader, M. A. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem. 2005, 48, 3663-79.
11. 3 receptors in the addictive properties of ethanol. Drugs Today 2004, 40, 355-65.
12. 3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294, 1154-65.
13. 3 receptor antagonist. J. Med. Chem. 2003, 46, 4952-64.
14. Hadley, M. S.; Lightfoot, A. P.; MacDonald, G. J.; Stemp, G. Preparation of tetrahydrobenzazepines as modulators of dopamine D3 receptors useful as antipsychotic agents. WO 2002040471, 2001.
15. Bonanomi, G.; Damiani, F.; Gentile, G.; Hamprecht, D. W.; Micheli, F.; Tarsi, L.; Tedesco, G.; Terreni, S. Preparation of fused benzazepines having affinity for dopamine D3 receptor. WO 2005118549, 2005.
16. Hamprecht, D.; Micheli, F.; Tarsi, L.; Tedesco, G. Preparation of 7-pyrazolylbenzazepines having affinity for D3 receptor. WO 2005123717, 2005.
17. Bonanomi, G.; Cardullo, F.; Damiani, F.; Gentile, G.; Hamprecht, D.; Micheli, F.; Tarsi, L. Preparation of fused benzazepines having affinity for the dopamine D3 receptor. WO 2006002928, 2005.
18. Arista, L.; Bonanomi, G.; Damiani, F.; Hamprecht, D.; Micheli, F.; Tarsi, L.; Tedesco, G. Preparation of tetrahydrobenzazepine derivatives as modulators of dopamine D3 receptors. WO 2005087764, 2005.
19. ACD Labs suite is available from http://www.acdlabs.com.
20. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties. J. Med. Chem. 2000, 43, 3714-3717.
21. The research complied with national legislation and with company policy on the Care and Use of Animals and with related codes of practice.
22. Aptuit Limited, 3 Simpson Parkway, Livingston, West Lothian, EH54 7BH, Scotland, www.aptuit.uk.
23. CERB, Chemin de Montifault, 18800 Baugy, France, www.cerb.fr.
24. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. 2006, 49, 5029-5046.
25. Mitcheson, J. S.; Chen, J.; Lin, M.; Culberson, C.; Sanguinetti, M. C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12329-333.
26. Sanguinetti, M. C.; Mitcheson, J. S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26, 119-124.
27. Oesterberg, F.; Aqvist, J. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods. FEBS Lett. 2005, 579, 2939-2944.
28. Dunbrack, R. L., Jr.; Karplus, M. Backbone-dependent rotamer library for proteins. Application to side-chain prediction. J. Mol. Biol. 1993, 230, 543-74.
29. 3 receptor antagonist (SB-2770110-A) attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol. Biochem. Behav. 2005, 81, 190-197.
30. 3 receptor antagonists improve the learning performance of memory-impaired rats. Psychopharmacology 2005, 179, 567-575.
31. Lacroix, L. P.; Ceolin, L.; Zocchi, A.; Varnier, G.; Garzotti, M.; Curcuruto, O.; Heidbreder, C. A. Selective dopamine D(3) receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J. Neurosci. Methods 2006, 157, 25-31.
32. Schwarz, A.; Gozzi, A.; Reese, T.; Bertani, S.; Crestan, V.; Hagan, J.; Heidbreder, C.; Bifone, A. Selective dopamine D3 receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse 2004, 54, 1-10.
33. Okauchi, T.; Suhara, T.; Maeda, J.; Kawabe, K.; Obayashi, S.; Suzuki, K. Effect of endogenous dopamine on endogenous dopamine on extrastriated [(11)C]FLB 457 binding measured by PET. Synapse 2001, 41, 87-95.
34. Burris, K. D.; Filtz, T. M.; Chumpradit, S.; Kung, M. P.; Foulon, C.; Hensler, J. G.; Kung, H. F.; Molinoff, P. B. Characterization of [125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3′-iodo-2′-propenyl)amino] tetralin binding to dopamine D3 receptors in rat olfactory tubercle. J. Pharmacol. Exp. Ther. 1994, 268, 935-942.
35. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
36. Dewey, S. L.; Brodie, J. D.; Gerasimov, M.; Horan, B.; Gardner, E. L.; Ashby, C. R., Jr. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999, 31, 76-86.
37. Horan, B.; Smith, M.; Gardner, E. L.; Lepore, M.; Ashby, C. R., Jr. (-)-Nicotine produces conditioned place preference in Lewis, but not Fischer 344 rats. Synapse 1997, 26, 93-94.
38. Horan, B.; Gardner, E. L.; Dewey, S. L.; Brodie, J. D.; Ashby, C. R., Jr. The selective sigma(1) receptor agonist, 1-(3,4-dimethoxyphenethyl)-4- (phenylpropyl)piperazine (SA4503), blocks the acquisition of the conditioned place preference response to (-)-nicotine in rats. Eur. J. Pharmacol. 2001, 426, R1-2.
39. 3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003, 28, 1272-1280.
40. 3 receptors in oral operant ethanol reinforcement and reinstatement of ethanol seeking responding in mice. Addict. Biol. 2007, 12, 35-50.
41. Schwarz, A. J.; Reese, T.; Gozzi, A.; Bifone, A. Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course. Magn. Reson. Imaging 2003, 21, 1191-1200.
42. Schwarz, A.; Whitcher, B.; Reese, T.; Gozzi, A.; Bifone, A. In Group-level data-driven phMR1 analysis. Proceedings of the International Society for Magnetic Resonance in Medicine, 2005, 13, 157.
43. Kaab, S.; Dixon, J.; Due, J.; Ashen, D.; Nabauer, M.; Beuckelmann, D. J.; Steinbeck, G.; McKinnon, D.; Tomaselli, G. F. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 1998, 98, 1383-1393.
44. Torres, A. M.; Bansal, P. S.; Sunde, M.; Clarke, C. E.; Bursill, J. A.; Smith, D. J.; Bauskin, A.; Breit, S. N.; Campbell, T. J.; Alewood, P. F.; Kuchel, P. W.; Vandenberg, J. I. Structure of the HERG K+ Channel S5P Extracellular Linker: Role of an Amphipathic .alpha.-Helix in C-Type Inactivation. J. Biol. Chem. 2003, 278, 42136-42148.
45. www.accelrys.com.
46. Magis, C.; Gasparini, D.; Lecoq, A.; Le Du, M. H.; Stura, E.; Charbonnier, J. B.; Mourier, G.; Boulain, J.-C.; Pardo, L.; Caruana, A.; Joly, A.; Lefranc, M.; Masella, M.; Menez, A.; Cuniasse, P. Structure-Based Secondary Structure-Independent Approach To Design Protein Ligands: Application to the Design of Kv1.2 Potassium Channel Blockers. J. Am. Chem. Soc. 2006, 128, 16190-16205.
47. Blaney, F. E.; Tennant, M. Computational tools and Tesults in the construction of G protein-coupled receptor models. In Membrane Protein Models; Findlay, J. B. C., Ed.; Bios Scientific Publishers Ltd., Oxford, UK, 1996; pp 161-176.
48. Polczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. 2000. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
49. Shi, L.; Simpson, M. M.; Ballesteros, J. A.; Javitch, J. A. The First Transmembrane Segment of the Dopamine D2 Receptor: Accessibility in the Binding-Site Crevice and Position in the Transmembrane Bundle. Biochemistry 2001, 40, 12339-12348.
50. www.wavefun.com.
51. An undesirable feature of some drugs is their ability to delay cardiac repolarization, an effect that can be measured as prolongation of the QT interval on the surface electrocardiogram (ECG). Because of its inverse relationship to heart rate, the QT interval is routinely transformed (normalized) by means of various formulas into a heart rate independent "corrected" value known as the QTc interval. The QTc interval is intended to represent the QT interval at a standardized heart rate of 60 bpm.